Biotech/Medical Tech Stock News from Investorideas.com

Monday, October 31, 2011

Biotech Stock Alert; Aethlon Medical (OTC: AEMD) Trading Up over 19%

Point Roberts, WA- October 31, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert for Aethlon Medical (OTCBB: AEMD), a Company developing therapeutic filtration devices to address infectious disease and cancer .The stock is trading up at $0.0810, up 0.0130 (19.12%), with a morning high of $0.0870 (up 27%) on over 1.2 Million shares.

The Company reported news at the beginning of October that it was awarded a $6.8 million contract from the Defense Advanced Research Projects Agency (DARPA) to develop a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection that is often the cause of death in combat-injured soldiers.

On October 18th, the Company reported that it will begin accepting orders for its Enzyme Linked Lectin Specific Assay (ELLSA™) from researchers that require a highly sensitive diagnostic tool to detect the presence of exosomes in cell culture, ascites, and other biological fluids, including blood.

Biotech Investor Snapshot for Aethlon Medical (OTCBB: AEMD)
The Aethlon Medical mission is to create innovative medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Our Aethlon ADAPT™ System is a revenue-stage technology platform that provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system. The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer; HER2osome™ to target HER2+ breast cancer, and a medical device being developed under a contract with the Defense Advanced Research Projects Agency (DARPA) that would reduce the incidence of sepsis in combat-injured soldiers and civilians. For more information, please visit www.aethlonmedical.com.

Visit the AEMD showcase page on Investorideas.com
http://www.investorideas.com/CO/AEMD

Get biotech news and stock alerts
http://www.investorideas.com/Resources/Newsletter.asp

Research more biotech stocks at the Biotech stocks Directory: http://www.investorideas.com/BIS/Stock_List.asp

About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas

Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. AETHLON MEDICAL INC(OTC BB: AEMD ) Showcase biotech, biodefense and defense stock on Investorideas.com ( $one thousand five hundred per month, $five thousand per month in 144 stock)Effective March 15, 2011
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411 - Source – www.Investorideas.com

Wednesday, October 26, 2011

TSX Biotech Stock News Alert; Verisante's (TSX.V: VRS) Aura™ has ability to revolutionize the way skin cancer is diagnosed

October 26, 2011 - Investorideas.com, a leader in sector research for independent investors issues an investor snapshot for TSX biotech stock, Verisante (TSX-V: VRS) following its October 19 th news, receiving Health Canada's approval for their innovative skin cancer detection device. The stock immediately moved up to over $1.00 on significant volume once the news was disseminated.

Verisante Receives Health Canada Approval for Verisante Aura(TM)!
VANCOUVER, BRITISH COLUMBIA -(10/19/11)- Verisante Technology, Inc. (TSX-V: VRS) (OTCQX: VRSEF.PK)(PINK SHEETS: VRSEF) a leader in cancer imaging technology, announced today that it has obtained a license from Health Canada to market and sell the Verisante Aura™, an innovative, non-invasive medical device for the early detection of skin cancer.
"Obtaining a license from Health Canada means we are now able to begin marketing and selling Verisante Aura™ in Canada. This is a defining milestone for our Company," said President and CEO Thomas Braun. " Our technology has the ability to revolutionize the way skin cancer is diagnosed, saving lives and costs. Verisante Aura™ will aid healthcare professionals in assessing skin lesions, reducing patient wait times and decreasing healthcare costs by detecting skin cancer at an early and most easily treatable stage."
Investorideas.com Newswire

Verisante Technology, Inc Key Facts:
Revolutionary, patent-protected, platform technology!

Applicable to several forms of cancer
Clear regulatory pathway that will result in significant early revenue
Imaging device for the safe detection of skin cancer now approved for sale in Canada
Strategic alliances with leading institutions
World class scientific capability
Project management led by experienced, award-winning pioneers
Medical and technical team led by renowned experts
Highly qualified management, and Strong, independent board
Raised $8.7 million in 2011, ensuring sufficient funding through commercialization

About Verisante Technology Inc.
Verisante Technology, Inc. is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Company's device for skin cancer detection, Aura™, is approved for sale in Canada. Approval in Europe and Australia is expected by the end of 2011. Verisante's AuraTM and Core™ (for lung, colon and cervical cancer detection) devices utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. This exclusive platform technology allows Verisante to develop compact, non-invasive cancer detection devices that offer immediate results for many of the most common cancers. Visit www.verisante.com
Company Contact
Verisante Technology, Inc.
306 - 2309 West 41st Avenue
Vancouver BC V6M 2A3
Tel 604 605 0507
Fax 604 605 0508
info@verisante.com
verisante.com
TSX-V: VRS
OTCQX: VRSEF
FRANKFURT: V3T
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks

, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists

and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising

.
Disclosure: Investorideas.com has been compensated one thousand to advertise Verisante technology and distribute news releases and content on their behalf by a third party IR firm. All information in this report is within the public domain and previously released by the company. All investment involves risk and possible loss of investment.
BC Residents and Investor Disclaimer : Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894
800-665-0411
Source - www.Investorideas.com

Tuesday, October 25, 2011

Biotech/Biodefense Stock News; Aethlon Medical (OTCBB: AEMD) to Present at IN3 Medical Innovation Summit on October 27th

SAN DIEGO � October 25, 2011 (Investorideas.com newswire) - Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announces that Chairman and CEO James A. Joyce will present a company overview, discuss recent developments and review upcoming milestones at the medical device partnering conference: Investment-In-Innovation (IN3) SUMMIT on October 27th in San Francisco, CA at the Intercontinental Mark Hopkins Hotel. IN3 events bring together early/mid/late-stage, medical technology innovators with investors, venture capitalists, and business development executives.

IN3 Summit is the largest annual strategic partnership and investment meeting for senior-level medical technology executives. Leading venture capital firms and corporate acquirers are expected to attend to hear the latest innovations and investment opportunities.
About Aethlon Medical
The Aethlon Medical mission is to create innovative devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. The Aethlon ADAPT™ system is an expansive technology platform that converges affinity drug agents and plasma membrane technology to create therapeutic filtration devices that selectively target the removal of harmful particles from the entire circulatory system. Our lead therapeutic candidate is the Aethlon Hemopurifier®, a device with broad-spectrum capabilities against viral pathogens and immunosuppressive cancer exosomes. In human studies, Hemopurifier® therapy has provided significant viral load reductions in HIV and hepatitis C virus infected individuals without the administration of antiviral drugs. We are now focused on advancing our Hemopurifier® as an adjunct strategy to improve the benefit of established infectious disease and cancer treatment regimens. Based on studies conducted by government and non-government research organizations, the Hemopurifier® is also a leading broad-spectrum treatment candidate to address bioterror and pandemic threats. For more information, please visit www.aethlonmedical.com.
Contacts:
James A. Joyce
Chairman, CEO
858.459.7800 x301
jj@aethlonmedical.com
Jody Cain
Senior Vice President, Lippert/Heilshorn & Associates
310.691.7100
jcain@lhai.com
Jim Frakes
Chief Financial Officer
858.459.7800 x300
jfrakes@aethlonmedical.com
John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
jps@aethlonmedical.com

AETHLON MEDICAL INC (OTC BB: AEMD) is a Showcase biotech, biodefense and defense stock on Investorideas.com
Visit the AETHLON MEDICAL INC (OTC BB: AEMD) showcase profile page

Disclosure/Disclaimer: AETHLON MEDICAL INC (OTC BB: AEMD) is a paid advertising client ($one thousand five hundred per month, $five thousand per month in 144 stock)

Monday, October 24, 2011

Q&A Interview with CEO of BioSante Pharmaceuticals (NasdaqGM: BPAX) Following News of Positive LibiGel® Safety Data Review in Phase III Program

Point Roberts

, WA - October 24, 2011- Investorideas.com, an investor research portal specializing in sector research including biotech and pharma stocks, issues an exclusive Q&A with Mr. Stephen M. Simes, President and Chief Executive Officer ofBioSante Pharmaceuticals, Inc. (NasdaqGM: BPAX).

The Company reported news earlier this month of positive LibiGel® safety data review in the Phase III program. Mr. Simes explains the significance of the data and what's next to take
LibiGel (testosterone gel) to market for the millions of women anxiously awaiting an approved FDA solution for female sexual dysfunction.
BioSante Pharmaceuticals Interview
Q: Investorideas.com
In the Company's last release, it was reported that "The DMC once again has recommended that the safety study continue as per the FDA-agreed protocol, without modification as there were no general or specific safety issues based on their unblinded review of adverse events."
Based on competitors dropping out of the market due to lack of sufficient safety data how significant is it that BioSante has reached this stage?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
Very significant. BioSante is conducting the largest safety study ever undertaken for a drug in the treatment of female sexual dysfunction. We are in the fourth year of a cardiovascular event and breast cancer safety study having completed enrollment at 3,656 women equally randomized to LibiGel or placebo. The Independent data monitoring committee has recommended continuing the study as per FDA-agreed protocol based on their seventh unblinded review of all safety data. We expect to be able to demonstrate the safety of LibiGel for the treatment of female sexual dysfunction.
Q: Investorideas.com
Can you explain to investors the next steps prior to filing an NDA in 2012?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We now have completed two LibiGel Phase III efficacy trials of over 500 women each. We expect to announce top-line efficacy data in December of this year. The LibiGel safety study will undergo its primary safety analysis next summer which will put us in position to submit the new drug application (NDA) by the end of 2012. Bases on positive safety and efficacy data we hope to receive FDA approval by mid-2013.
Q: Investorideas.com
LibiGel is currently the only product in Phase III clinical development for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), with an estimated market of $2 billion. How does the Company see the revenue stream following FDA approval?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
We expect that the market for the treatment of female sexual dysfunction will be over $2 billion, which is the size of the erectile dysfunction market in the U.S. Based on published reports we believe the market for FSD will be at least that large. In addition, in 2010, there were about four million testosterone prescriptions written off-label for women, and in primary research doctors tell us they will switch over 90 percent of the off-label use to an FDA approved product.
Q: Investorideas.com
Several analysts including Rodman & Renshaw have a 12- month price target of $5.00 or more on the stock. The stock has had a 52-wwek high of just over $4.00 and has fallen back… What do you say to that?
A: Stephen M. Simes, President and Chief Executive Officer of BioSante Pharmaceuticals
These are very difficult times in the market and in the economy. We believe our stock price is not reflecting accurately our true value. As we continue to make progress we would expect our stock price to reflect our true value. Happily we are in a very solid cash position with over $73 million in cash as of August 31, 2010 with an approximate $4 million/month burn rate which should decrease to about $3 million/month in 2012.
About LibiGel ®
LibiGel is a testosterone gel in Phase III clinical development for the treatment of women who suffer from female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD). The completed Phase III efficacy trials are double-blind, placebo-controlled trials that enrolled over 500 surgically menopausal women each for six-months of therapy. The completed efficacy trials were conducted according to an FDA-agreed special protocol assessment (SPA) agreement. LibiGel is absorbed quickly through the skin after applying a once-daily pea-sized topical application on the upper arm that delivers testosterone to the bloodstream evenly over time.
In a Phase II trial, LibiGel significantly increased the number of satisfying sexual events in surgically menopausal women suffering from FSD by 238 percent versus baseline (p<0.0001); this increase also was significant versus placebo (p<0.05). In this study, the effective dose of LibiGel produced testosterone blood levels within the normal range for pre-menopausal women and had a safety profile similar to that observed in the placebo group. In addition, no serious adverse events and no discontinuations due to adverse events occurred in any subject receiving LibiGel. The Phase II clinical trial was a double-blind, placebo-controlled trial, conducted in the United States

, in surgically menopausal women distressed by their low sexual desire and activity.
About BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX)
About BioSante Pharmaceuticals, Inc.
BioSante is a specialty pharmaceutical company focused on developing products for female sexual health and oncology. BioSante's lead products include LibiGel ® (transdermal testosterone gel) for the treatment of female sexual dysfunction (FSD), specifically hypoactive sexual desire disorder (HSDD), which is in Phase III clinical development according to a U.S. Food and Drug Administration (FDA) Special Protocol Assessment (SPA). BioSante's first FDA-approved product is Elestrin™ (estradiol gel) indicated for the treatment of hot flashes associated with menopause, marketed in the U.S. by Azur Pharma, BioSante's licensee. BioSante also is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials. Other BioSante products are Bio-T-Gel™, a testosterone gel for male hypogonadism, for which an NDA is pending, licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development. Additional information is available online at: www.biosantepharma.com.
Forward-Looking Statements
or revise any forward-looking statement, whether as a result of new information, future events or otherwise. To the extent any statements made in this news release deal with information that is not historical, these are forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante's plans, objectives, expectations and intentions with respect to its future operations and products, the timing of anticipated clinical development milestones and regulatory submissions and other statements identified by words such as "will," "could," "believes," "intends," "continue," "plans," "expects," "anticipates," "may," other words of similar meaning, derivatives of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante's actual results to be materially different than those expressed in or implied by BioSante's forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the success of clinical testing; and BioSante's need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante's actual results are described in BioSante's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. All forward-looking statements in this news release speak only as of the date of this news release. BioSante undertakes no obligation to update
For more information, please contact:
For Investors:
The Trout Group LLC
Tricia Swanson
(646) 378-2953 tswanson@troutgroup.com
For Media:
Harris D. McKinney, Inc.
Alan Zachary
(312) 506-5220 azachary@harrisdmckinney.com
About InvestorIdeas.com:
InvestorIdeas.com is a leader in investor stock research by sectors. Sectors we cover include; water stocks, gold and mining stocks, China stocks, oil and gas stocks, renewable energy stocks, coal stocks, tech stocks, biotech stocks, defense stocks, nanotech, agriculture and gaming.
Follow Investorideas.com on Twitter http://twitter.com/#!/Investorideas
Follow Investorideas.com on Facebook http://www.facebook.com/Investorideas
Disclaimer/ Disclosure : The Investorideas.com is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising. BioSante is a paid advertising biotech stock on Investorideas.com (six thousand five hundred for three months)
Source - Investorideas.com 800-665-0411

Tuesday, October 18, 2011

Biotech Stock Alert; (OTC: AEMD) Trading Up 21% on News of Availability of its Exosome Detection Assay

Point Roberts, WA- October 18 , 2011- Investorideas.com , an investor research portal specializing in sector research including biotech and pharma stocks, report Aethlon Medical (OTCBB: AEMD), a pioneer in developing therapeutic filtration devices is trading up at 0.08, up 0.0140 (21.21%) in late morning trading on over 450,000 shares.

The Company reported news on the opening that it will begin accepting orders for its Enzyme Linked Lectin Specific Assay (ELLSA™) from researchers that require a highly sensitive diagnostic tool to detect the presence of exosomes in cell culture, ascites, and other biological fluids, including blood.

Disclaimer

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp